

Emergent BioSolutions Inc.  
Form 4  
March 02, 2017

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Kramer Robert

(Last) (First) (Middle)

400 PROFESSIONAL DR, SUITE 400

(Street)

GAITHERSBURG, MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
Emergent BioSolutions Inc. [EBS]

3. Date of Earliest Transaction (Month/Day/Year)  
02/28/2017

4. If Amendment, Date Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

EVP, Corporate Services Div

6. Individual or Joint/Group Filing (Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount (A) or (D) Price		
Common Stock <sup>(1)</sup>	08/01/2016		J		1,672 A \$ 0	70,000	D
Common Stock <sup>(2)</sup>	08/01/2016		J		1,061 A \$ 0	71,061	D
Common Stock <sup>(3)</sup>	08/01/2016		J		1,425 A \$ 0	72,486	D
Common Stock <sup>(4)</sup>	02/28/2017		A		8,161 A \$ 0	80,647	D
Common Stock	02/28/2017		A		8,162 <sup>(5)</sup> A \$ 0	88,809	D

Edgar Filing: Emergent BioSolutions Inc. - Form 4

Common Stock      02/28/2017      F      1,799      D      \$ 30.63      87,010      D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**      SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable      Expiration Date	Title      Amount or Number of Shares
Employee Stock Option (Right to buy)	\$ 25.62	08/01/2016		J	1,672	<u>(7)</u> 03/10/2021	Common Stock      1,672
Employee Stock Option (Right to buy) <sup>(8)</sup>	\$ 26.45	08/01/2016		J	2,121	<u>(6)</u> 03/09/2022	Common Stock      2,847
Employee Stock Option (Right to buy) <sup>(9)</sup>	\$ 30.86	08/01/2016		J	2,847	<u>(6)</u> 02/28/2023	Common Stock      2,847
Employee Stock Option (Right to buy)	\$ 30.63	02/28/2017		A	32,638	<u>(8)</u> 02/27/2024	Common Stock      32,638

## Reporting Owners

Reporting Owner Name / Address

Relationships

